Tarsus Pharmaceuticals is tackling a common eyelid condition affecting millions of Americans with its recently launched Look at the Lids campaign.
The educational effort targets demodex blepharitis, an eye condition caused by demodex mites and resulting in eyelid inflammation, redness and eye irritation. The uncomfortable condition affects approximately 25 million Americans.
Frills, a waxy debris made up of discarded mite waste and eggs, are often found on the eyelid as a sign of demodex blepharitis.
Look at the Lids urges eye care professionals to screen all patients for the disease as part of an effort to diagnose and treat the disease earlier.
Tarsus is unveiling the campaign at two industry events: the 2022 Annual Meeting of the American Academy of Ophthalmology as well as the Annual Meeting of the American Academy of Optometry.
At both functions, Tarsus has an interactive exhibit booth that will create a virtual tattoo on attendees’ eyelids and let them see what the ruffs that cause demodex blepharitis look like. Eye care professionals will also be able to add their own eyelid photos to a video wall in real time.
Tarsus CEO Bobak Azamian, MD, PhD, said Look at the Lids focuses on the importance of behavior change among physicians by identifying the root causes of demodex blepharitis. Focusing on the visual aspects of the disease and diagnosing accordingly leads to earlier and more effective treatment, says Azamian.
“We ask doctors to look down because on a standard exam we know that if patients have frills they will have demodex blepharitis,” he said. “This is a patient-oriented campaign asking doctors to look at the main signs of this disease in order to diagnose this disease.”
Azamian added that Tarsus is seeking to combat the disease with diagnostics as well as the promise of TP-03, the company’s new investigational therapeutic treatment that is currently under review by the Food and Drug Administration.
He noted that while some may overlook eye care as an aspect of health care, the risks associated with deteriorating vision can be costly for patients.
“What I realized back when I was a doctor, investor, and entrepreneur is that if we don’t have sight, nothing else really matters,” he said. -he declares. “It’s an important part of the pharmaceutical industry, especially with an aging population, where we will increasingly focus on diseases affecting our eyes. Symptoms range from what patients can see, whether their eyes feel fine, or whether they are able to see at all. This is the range of considerations that pharmaceutical companies in our space are looking for.
Beyond Look at the Lids, Tarsus recently appointed Scott Morrison, who has held various leadership positions at Ernst & Young over the past 20 years, as a member of its board of directors and chairman of the management committee. audit.